Bio Developments

Pic:getty/ERproductionslimited

NIH awards $577m to antiviral drug developers

By Rachel Arthur

The National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health, has awarded a total of $577m to establish nine Antiviral Drug Discovery (AViDD) Centers for Pathogens of Pandemic Concern.

© GettyImages/Artur

NPD Gallery: Technology Insider

By Jane Byrne

We track developments and launches in process engineering tools and research components over the past few weeks.

Pic:getty/hailshadow

Developing vaccines against Epstein-Barr virus

By Rachel Arthur

Last week the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, launched a clinical trial to investigate a preventative vaccine for Epstein-Barr virus (EBV). It’s part of growing efforts to create...

Pic:getty/sohelparvezhaque

Pfizer acquires RSV therapeutic candidates

By Rachel Arthur

Pfizer will acquire ReViral, a privately-held clinical-stage company which is focused on novel antiviral therapeutics for respiratory syncytial virus (RSV), for up to $525m.

Pic:getty/jonathanknowles

Ocugen starts clinical trials for retinal gene therapy candidate

By Rachel Arthur

The first patient has been dosed in the Phase 1/2 clinical trial of OCU400, a modifier gene therapy candidate for the treatment of retinitis pigmentosa (RP) resulting from mutations in the nuclear receptor subfamily 2 group E member 3 (NR2E3) and Rhodopsin...

Pic:getty/andrewbrookes

Biogen releases long-term Aduhelm data

By Rachel Arthur

Biogen has announced new Phase 3 data showing that, after nearly 2.5 years of treatment, Aduhelm continued to reduce two key Alzheimer’s disease pathologies.

Pic:getty/coffeekai

Moderna initiates Phase 3 trial for RSV vaccine candidate

By Rachel Arthur

Moderna has initiated the Phase 3 portion of its pivotal respiratory syncytial virus (RSV) vaccine trial: looking towards its ultimate goal to combine the vaccine with its COVID-19 and flu boosters into a single dose booster.

Two of the new vaccine candidates target latent viruses. Pic:getty/artemisdiana

Moderna targets shingles in mRNA pipeline expansion

By Rachel Arthur

Moderna is expanding its mRNA pipeline with three new development programs: with vaccine candidates against herpes simplex virus (HSV), varicella-zoster virus (VSV) and a new checkpoint cancer vaccine.

Pic:getty/stockcolors

AffaMed Therapeutics obtains IND clearance for novel retinal biologic

By Rachel Arthur

AffaMed Therapeutics has announced that the US FDA has cleared its Investigational New Drug (IND) application for the clinical development of AM712 (ASKG712), a novel proprietary bispecific biologic molecule blocking both vascular endothelial growth factor...